Find policies, billing codes, payers, states, and providers
Pancreatic Enzyme Testing for Acute Pancreatitis
Customize your policy alerts
Sign up for all Oscar Health policy alerts
Know when Oscar Health releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs coverage and reimbursement for laboratory measurement of pancreatic enzymes (lipase, amylase, trypsinogen/TAP, and selected inflammatory biomarkers) for diagnosis and management of acute pancreatitis for Oscar Health members and providers submitting claims to Oscar.
Coverage Criteria for Pancreatic Enzyme and Biomarker Testing
Serum lipase — medically necessary
Covered when ALL of the following are met
Signs/symptoms listed in Note 1 (epigastric pain, nausea, vomiting, tender epigastrium, hypotension, tachypnea, hypoxemia, Cullen/Grey Turner signs, etc.)
Amylase, trypsin(ogen), TAP, and listed biomarkers — not medically necessary
Not covered (does not meet criteria)
Also: measurement of serum lipase in situations not described (i.e., absence of signs/symptoms of AP) does not meet criteria.
Initial diagnostic testing
Diagnostic testing for suspected acute pancreatitis is aligned to the Atlanta criteria and guideline recommendations.
Diagnostic criteria per Atlanta/Guidelines
- Biochemical testing preference: Serum lipase is preferred over amylase due to higher sensitivity and specificity across multiple studies.
Multiple cohort, prospective and retrospective studies summarized support lipase superiority (see cited evidence).
Severity assessment
Markers for severity assessment and monitoring (adjunctive to clinical scoring and imaging).
These markers are adjuncts and not replacements for clinical scores (BISAP, APACHE-II) or imaging.
Trypsin/TAP testing
Point-of-care trypsin/trypsinogen/TAP testing
Routine use not endorsed in major guidelines; utility is debated.
Initial diagnostic testing for suspected acute pancreatitis
Covered when ALL of the following are met
Serum lipase is preferred over amylase for initial testing per guideline recommendations.
Monitoring established pancreatitis
Repeat lipase testing is restricted
CADTH recommends minimal retesting intervals and advises not to routinely repeat lipase; exception allowed for suspected acute-on-chronic disease.
Measurement of serum amylase is excluded from coverage except when ordered specifically for analysis of pancreatic cyst fluid. The policy language states that amylase testing "when ordered for anything other than analysis of pancreatic cyst fluid, measurement of amylase DOES NOT MEET CRITERIA," so amylase requests should be limited to the cyst-fluid context to be considered appropriate.
Routine repeat serial testing of amylase and lipase during an inpatient stay is discouraged due to lack of demonstrated benefit for severity or outcome and because it increases costs and downstream resource use. Published analyses found no difference in disease severity between patients who had repeat enzyme testing and those who did not, and large retrospective studies link routine ED lipase ordering to unnecessary imaging and consultations.
Ordering both serum amylase and lipase concurrently for suspected acute pancreatitis is discouraged. Multiple professional recommendations and guideline summaries advise preferring lipase alone because co-ordering increases costs while providing only marginal improvement in diagnostic yield compared with lipase by itself.
Selected literature and evidence sources supporting the policy are listed in the references section (Evidence-based Scientific References), which includes systematic reviews, cohort studies, and guideline documents informing diagnostic thresholds, comparative accuracy of lipase versus amylase, and retesting guidance.
Broad, non‑indicated screening orders for serum lipase in patients without abdominal pain or clinical suspicion of pancreatitis are discouraged. The policy notes that measurement of lipase in situations not described (absence of signs/symptoms) does not meet criteria, and cohort data have shown that routine ED lipase testing can lead to unnecessary imaging, consultations, and additional costs.
The policy discourages broad, non‑indicated screening orders for pancreatic enzyme testing. Evidence cited shows that overuse of lipase (and concurrent amylase) results in unnecessary downstream testing and expense, and stewardship approaches (removal of amylase from common order sets, limits on repeat testing) have been associated with reduced co‑ordering and cost savings.
Routine repeat serum lipase testing to monitor an established diagnosis of acute or chronic pancreatitis is not considered medically necessary except when there is clinical suspicion of acute‑on‑chronic pancreatitis. Guidance from an evidence review panel recommends not reordering lipase for monitoring and suggests implementation of minimum retesting intervals to reduce unnecessary retesting.
The excerpted section does not contain explicit additional 'not medically necessary' statements beyond those already summarized; the following pages list the evidence‑based scientific references that underpin the policy recommendations.
Codes, Thresholds, and Diagnostic Values
| No codes listed |
| 82150 | Amylase |
| 83519 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, by radioimmunoassay (eg, RIA) |
| 83520 | Immunoassay for analyte other than infectious agent antibody or infectious agent antigen; quantitative, not otherwise specified |
| 83529 | Interleukin-6 (IL-6) |
| 83690 | Lipase |
| 84145 | Procalcitonin (PCT) |
| 86140 | C-reactive protein |
| 86141 | C-reactive protein; high sensitivity (hsCRP) |
Provider Responsibilities, Documentation, and Billing Impact
Prior authorization
No explicit prior authorization requirement is stated in this portion of the policy; coverage is determined by medical necessity and the member's benefit at time of request.
Prior authorization / utilization review note
Although no prior authorization is specified, testing that appears routine or without clinical indication (for example broad screening lipase orders) may be subject to utilization review and potential denial due to evidence of overuse and downstream costs.
Procedure codes (reference)
Reference procedure codes for tests related to this policy are listed for billing and coding use; prior authorization requirements are not specified here.
Prior authorization — not specified
No prior authorization requirements are stated in the provided content.
Step therapy
Step therapy is not specified in this section of the policy.
Provider actions — none specified
No additional provider action requirements are specified in this excerpt.
Preferred test order
Order serum lipase (not amylase) for initial evaluation of suspected acute pancreatitis; do not routinely order both lipase and amylase.
- Serum lipase is preferred over amylase due to improved sensitivity and a longer diagnostic window.
- Ordering both tests is discouraged because it increases costs with minimal diagnostic benefit.
Step therapy — none specified
No step therapy requirements are specified in this excerpt.
Required documentation
Provide documentation that the serum lipase test is ordered for a patient presenting with signs or symptoms of acute pancreatitis (see Note 1) and that outpatient lipase testing is limited to one test per day.
- Include clinical signs/symptoms from Note 1 (e.g., epigastric pain, nausea, vomiting).
- Document timing of test and rationale for repeat testing if applicable.
Required clinical documentation
Document clinical features consistent with acute pancreatitis when using enzyme testing: characteristic abdominal pain, enzyme elevation >=3× ULN, or imaging consistent with pancreatitis; include relevant labs (triglycerides, calcium, liver chemistries) per guideline recommendations.
- Record whether at least two diagnostic criteria are present (Atlanta criteria).
- Record ancillary labs (triglycerides, calcium, liver chemistries) obtained on admission.
Diagnostic documentation
When using enzyme testing to support diagnosis, document the presence of at least two diagnostic criteria: characteristic abdominal pain; serum amylase or lipase ≥3× the upper limit of normal; or imaging consistent with pancreatitis.
- If enzyme elevation is used, specify numeric relation to laboratory ULN (≥3×).
Evidence references — no documentation requirements in this excerpt
This section contains literature references and does not include additional documentation requirements for claims or testing beyond those stated elsewhere in the policy.
Denial triggers
Claims may be denied or recouped if coding/billing guidelines or reimbursement policies are not followed; tests that do not meet policy criteria (for example amylase except for pancreatic cyst fluid, trypsin/trypsinogen/TAP, listed biomarkers, or lipase when ordered without signs/symptoms) may be denied.
Overutilization risk
Routine or overutilized ordering of serum lipase—especially in the ED without clinical indication—can prompt unnecessary imaging, consultations, and added costs; documentation showing clinical indication may be necessary to avoid utilization-review actions.
Repeat testing denial risk
Repeat lipase testing to monitor established acute or chronic pancreatitis is not recommended and may be denied except when there is clinical suspicion of acute-on-chronic pancreatitis.
- Do not reorder lipase for monitoring established acute or chronic pancreatitis unless acute-on-chronic is suspected.
Authorization/denial rules — none present in this excerpt
No authorization or denial criteria beyond those already stated are present in this excerpt.
Background and Scope
Acute pancreatitis (AP) is inflammation of the pancreatic tissue and is commonly diagnosed when an individual meets at least two of three criteria: characteristic abdominal pain; serum amylase or lipase elevated ≥3× the upper limit of normal; or imaging consistent with pancreatitis. Serum lipase is the preferred biochemical marker because it typically rises within hours after pancreatic injury and remains elevated longer than amylase, providing a wider diagnostic window.
Definitions and Test Descriptions
Policy Revision History
Policy effective date updated to 2026-10-01.
Policy underwent review on 2026-06-16 (publication history notes 06/16/2026).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.